Articles related to COMBINATION THERAPY

The EV-302/KEYNOTE-A39 trial has demonstrated a significant improvement in survival outcomes for patients with advanced bladder cancer, with the combination of enfortumab vedotin and pembrolizumab nearly doubling the median progression-free survival and overall survival compared to chemotherapy.

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

The FDA’s recent approval of toripalimab, based on the JUPITER-02 and POLARIS-02 clinical trials, marks a significant milestone in the treatment of nasopharyngeal carcinoma. With a median progression-free survival of 11.7 months, toripalimab has shown promising results in improving patient outcomes.

The recent phase 1/2 study of Pfizer-BioNTech’s combination vaccine candidate demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. This promising development could significantly impact global immunization practices.

The approval of Combogesic IV, backed by data from two phase 3 studies, signifies a major breakthrough in our ongoing efforts to provide effective and safer alternatives to opioids for postoperative pain management.

This recent study suggests that systemic treatment with chemotherapy plus immunotherapy may allow patients with muscle-invasive bladder cancer (MIBC) to avoid radical cystectomy.